ChiCTR2100048381 版本V1.0 版本创建时间2022/02/12 09:30:43 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100048381 

最近更新日期:

Date of Last Refreshed on:

2021-07-06 04:36:06 

注册时间:

Date of Registration:

2021-07-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

血清Maresin1浓度与糖尿病肾病的相关性研究

Public title:

Study on the correlation between serum maresin 1 concentration and diabetic kidney disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

血清Maresin1浓度与糖尿病肾病的相关性研究

Scientific title:

Study on the correlation between serum maresin 1 concentration and diabetic kidney disease

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李欣悦 

研究负责人:

徐勇 

Applicant:

Xinyue Li 

Study leader:

Yong Xu 

申请注册联系人电话:

Applicant telephone:

15390379395

研究负责人电话:

Study leader's
telephone:

13980255895

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

735199356@qq.com

研究负责人电子邮件:

Study leader's E-mail:

xywyll@swmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省泸州市江阳区西南医科大学附属医院

研究负责人通讯地址:

四川省泸州市江阳区西南医科大学附属医院

Applicant address:

The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan

Study leader's address:

The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

西南医科大学附属医院

Applicant's institution:

The Affiliated Hospital of Southwest Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2020056

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西南医科大学附属医院临床试验伦理委员会

Name of the ethic committee:

Clinical Trial Ethics Committee, The Affiliated Hospital of Southwest Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-04-30 00:00:00

伦理委员会联系人:

张增瑞

Contact Name of the ethic committee:

Zengrui Zhang

伦理委员会联系地址:

西南医科大学附属医院

Contact Address of the ethic committee:

The Affiliated Hospital of Southwest Medical University

伦理委员会联系人电话:

Contact phone of the ethic committee:

0830-3165273

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

西南医科大学附属医院

Primary sponsor:

The Affiliated Hospital of Southwest Medical University

研究实施负责(组长)单位地址:

四川省泸州市江阳区西南医科大学附属医院医学实验中心

Primary sponsor's address:

The Affiliated Hospital of Southwest Medical University

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

泸州

Country:

China

Province:

Sichuan

City:

Luzhou

单位(医院):

西南医科大学附属医院

具体地址:

江阳区太平街25号

Institution
hospital:

The Affiliated Hospital of Southwest Medical University

Address:

25 Taiping Street, Jiangyang District

经费或物资来源:

西南医科大学附属医院

Source(s) of funding:

The Affiliated Hospital of Southwest Medical University

研究疾病:

糖尿病肾病  

Target disease:

diabetic kidney disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

本研究的目的是在人群中研究内源性maresin-1合成障碍与糖尿病肾病发展的相关性。  

Objectives of Study:

The aim of this study was to investigate the association between endogenous maresin-1 synthesis disorder and the development of diabetic nephropathy in a population.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①18-80岁
②参照 1999 年 WHO 标准诊断为2型糖尿病。T2DM 诊断标准: 参照1999 年 WHO 糖 尿病诊断及分型标准,典型糖尿病症状( 多饮、多尿、多食、体重下降) 加上随 机 血 糖 检 测 ≥11. 1 mmol/L,或加上空腹血糖检测≥7. 0mmol /L,或加上 葡萄糖负荷后 2h 血糖检测≥11. 1mmol /L。无糖尿病症状者,需改日重复检查。排除1型糖尿病、其他特殊类型糖尿病、妊娠糖尿病。

Inclusion criteria

① 18-80 years old
② The patient was diagnosed as type 2 diabetes according to the WHO standard in 1999.Diagnostic criteria for T2DM: according to the 1999 WHO criteria for the diagnosis and classification of glycemic and urinary diseases, typical diabetic symptoms (polydipsia, polyuria, polyphagia, weight loss) plus blood glucose test ≥11.1 mmol/L, or plus fasting blood glucose test ≥7.0mmol /L, or 2h blood glucose test after adding glucose load ≥11.The tendency for 1 / L.No symptoms of diabetes, need another day to repeat the examination.Type 1 diabetes, other specific types of diabetes, and gestational diabetes were excluded.

排除标准:

合并恶性肿瘤;合并各种非糖尿病肾病;合并严重胃肠道疾病(包括消化性溃疡、肝炎、炎症性肠病、肠结核、严重腹泻、便秘等);合并自身免疫性疾病;近期合并感染、发热;3个月内使用过抗生素;子痫前期及子痫患者;不合作者。

Exclusion criteria:

Complicated with malignant tumor;Complicated with various non-diabetic nephropathy;Complicated with serious gastrointestinal diseases (including peptic ulcer, hepatitis, inflammatory bowel disease, intestinal tuberculosis, severe diarrhea, constipation, etc.);Complicated with autoimmune diseases;Recent combined infection and fever;Use of antibiotics within 3 months;Patients with preeclampsia and eclampsia;Not the author.

研究实施时间:

Study execute time:

From 2020-09-01 00:00:00 To 2021-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-06-28 00:00:00 To 2021-08-15 00:00:00

干预措施:

Interventions:

组别:

正常蛋白尿组

样本量:

200

Group:

Normal albuminuria group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

微量蛋白尿组

样本量:

200

Group:

Microalbuminuria group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

大量蛋白尿组

样本量:

200

Group:

Mass albuminuria group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

泸州 

Country:

China

Province:

Sichuan

City:

Luzhou

单位(医院):

西南医科大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Affiliated Hospital of Southwest Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血清Maresin1浓度

指标类型:

主要指标

Outcome:

Serum Maresin1 concentration

Type:

Primary indicator

测量时间点:

测量方法:

酶联免疫吸附剂测定

Measure time point of outcome:

Measure method:

Enzyme-linked immunosorbent assay

指标中文名:

静脉血糖

指标类型:

次要指标

Outcome:

Venous blood sugar

Type:

Secondary indicator

测量时间点:

测量方法:

血清果糖胺测定

Measure time point of outcome:

Measure method:

Serum fructosamine determination

指标中文名:

血尿素氮

指标类型:

次要指标

Outcome:

Blood urea nitrogen

Type:

Secondary indicator

测量时间点:

测量方法:

酶促动力法

Measure time point of outcome:

Measure method:

Enzyme kinetic method

指标中文名:

血肌酐

指标类型:

次要指标

Outcome:

Serum creatinine

Type:

Secondary indicator

测量时间点:

测量方法:

酶促动力法

Measure time point of outcome:

Measure method:

Enzyme kinetic method

指标中文名:

尿微量白蛋白

指标类型:

次要指标

Outcome:

Urine trace albumin

Type:

Secondary indicator

测量时间点:

测量方法:

化学发光法

Measure time point of outcome:

Measure method:

Enzyme kinetic method and chemiluminescence

指标中文名:

肾小球滤过率

指标类型:

次要指标

Outcome:

Glomerular filtration rate

Type:

Secondary indicator

测量时间点:

测量方法:

酶促动力法

Measure time point of outcome:

Measure method:

Metagenomic Sequencing

指标中文名:

糖化血红蛋白

指标类型:

次要指标

Outcome:

Glycosylated hemoglobin

Type:

Secondary indicator

测量时间点:

测量方法:

化学发光法

Measure time point of outcome:

Measure method:

Chemiluminescence

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究员采用简单随机化分组方法产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

The random sequence is generated by the researcher using a simple randomization grouping method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

西南医科大学附属医院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Affiliated Hospital of Southwest Medical University

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-07-06 04:36:06